

C.V : DR. GOH ENG LEONG

- Name: Goh Eng Leong, Damien
- Age: 54 year
- Nationality: Malaysian

Working Experience

- 1994 to 1998: Houseman and medical officer in Penang General Hospital, Seberang Jaya Hospital
- 1998 to 2002: Clinical Specialist in Medical and Cardiology Department in Penang General Hospital
- 1999 to 2001: Lecturer in Penang Medical College (PMC)
- 2002 to 2003: Senior Lecturer in Penang Medical College
- 2003 - 2005: Adjunct Senior Lecturer in Penang Medical College
- Currently:
- Senior Consultant Cardiologist in Loh Guan Lye Specialists Centre
- Head of Department, Heart Centre, Loh Guan Lye Specialists Centre — since 2010
- Head of Department, Medical Department, Loh Guan Lye Specialists Centre — since 2020

Education and Qualification

- Undergraduate:
- Graduated from National University of Malaysia (University Kebangsaan Malaysia—UKM) in 1994. — Bachelor of Medical Science and Medical Doctor, MD (UKM)
- Postgraduate Qualifications:
- Member of Royal Colleges of Physicians of the United Kingdom — MRCP (UK) .
23/11/1998
- Master of Medicine (Internal Medicine) National University of Singapore —M Med (NUS) — 31/07/1998.

- Cardiology (Interventional) training:
 - Ministry of Health (MOH) of Malaysia in Penang Hospital from 1999 to 2002. (Trainers: Dato Dr Omar Ismail, Dr Simon Lo, Dr Sim Kui Hian, Dr Raj Kumar)
 - Interventional Cardiology Training in Mater Hospital, Dublin in 2002 (Trainer: Dr Declan Sugrue)
- National Specialists Registry (NSR) certified: Interventional Cardiologist : 21/06/2007
- Fellow of National heart association of Malaysia (FNHAM) -- 05/04/2008
- Member of Academy of Medicine (AM) -- 2009
- Fellow of College of Physicians Malaysia (FeCOP)— 3/12/2022

Award

- Excellent Service Award of Health Department of Penang State in 1998
— Sijil Perkhidmatan Cemerlang 1998, Jabatan Kesihatan Negeri Pulau Pinang

Activities

- President of Penang CPR Society since 2002 till now.
- Life Member of Malaysia Medical Association (MMA)
- Past Chairman of Malaysia Medical Association (Penang Branch)
- Life Member of Medico-legal Society of Malaysia
- Life Member of The Penang Medical Practitioners' Society (PMPS)
- Life Member of National Heart Association of Malaysia (NHAM) Since 2015
- Founding member of Penang Meducation — Promoting continuing professional development and education to physicians and cardiologists in Penang and Malaysia as well as internationally.
 - Organising committee member and Director for Penang Cardiovascular Conference (PCC) and Complex Cardiovascular Intervention (CCI)
 - Active in CPD activities in Penang and Malaysia.
 - Faculty of TCT Asia Pacific Seoul Korea 2018 and 2019

- Faculty of CCT KOBE JAPAN 2019
- Faculty of Virtual 5th Complex PCI Meeting 2020. Korea.
- Faculty of Virtual TCT Asia Pacific Meeting 2021.
- Professional Member of European Society of Cardiology (ESC)
- Reviewer of Medical Journal of Malaysia (MJM) — Since 2020
- Reviewer of Young Investigator Award of National Heart Association of Malaysia (NHAM) — Since 2018
- Preceptor for Menarini CANOPY Program (The stable Coronary Artery disease kKnowledge learning Program) — May 2020
- Advisor for Advisory Boards for:
 - Stroke Prevention for Atrial Fibrillation (SPAF)
 - Heart Failure Management
 - Lipid Lowering Management
- Receive honorarium as speaker from following pharmaceutical companies:
 - Pfizer, Merck, MSD, Astra Zeneca, Sanofi, Boeringher Ingelheim , Novartis, Menarini. Amgen, Servier, Sun Pharma

Research and Publication

A. Research Papers (Published)

A1. Original Articles

1. An audit on Management of Acute Asthma in Adults in the Medical Wards, Penang Hospital. Medical Journal Penang Hospital. Vol. 5, 2000/2001

A2. Abstracts

1. Reducing in Hospital Delay in Thrombolytic Therapy in Acute Myocardial Infarction. Penang Hospital. Medical Journal Penang Hospital. Vol. 5, 2000/2001.

2. Single Center Experience of Abxiximab (Repro) Usage as an Adjunctive Interventional Pharmacotherapy in Malaysia. Penang Hospital. Medical Journal Penang Hospital. Vol. 5, 2000/2001.

3. High incidence of hypercholesterolemia in newly diagnosed hypertensive patients. Time for Malaysian 'Framingham Study'. Penang Hospital. Medical Journal Penang Hospital. Vol. 5, 2000/2001.

4. The outcome of patients with small stents used during PTCA in Penang Hospital Cardiology Department. Penang Hospital. Medical Journal Penang Hospital. Vol. 5, 2000/2001

B. Research Papers (Oral Presentation)

1. What is new? A brief review on guidelines 2000 for CPR and emergency cardiovascular care — Abstract in 1st National Resuscitation

2. Outcome of fast track triage system in thrombolytic therapy for patient with acute MI— National Heart Association (NHA) Annual Scientific Meeting, 2000

3. Single Centre experience of Abciximab (Reopro) usage as an adjunctive interventional pharmacotherapy in Malaysia— NHA Annual Scientific Meeting, 2000

4. High incidence of hypercholesterolemia in newly diagnosed hypertensive patients: Time for Malaysia 'Framingham Study'— NHA Annual Scientific Meeting, 2000

5. The outcome of patients with small stents used during PTCA — National Heart Association Annual Scientific Meeting. This paper won the 'Best Young Investigator Award'

6. The outcome of patients with small stents used during PTCA— 13th ASEAN Congress of Cardiology,

7. "The first Penangham Study--- One year follow up of newly diagnosed Hypertensive patients"— Asia Pacific Atherosclerosis and Vascular Disease

8. (RASS) Renal Artery Stenosis Study — NHA Annual Scientific Meeting, 2001 This paper entered the finals for "Best Scientific Paper Award"

9. LARAS Study (Left Main Stem Disease and Renal Artery Stenosis)— NHA Annual Scientific Meeting, 2001

10. The Prevalence of Overweight Among Male Patients with Coronary Disease— NHA Annual Scientific Meeting, 2001

11. Acute Coronary Syndrome: Characteristics and Outcome in Penang Hospital— NHA Annual Scientific Meeting, 2001

12. The cardiovascular risk factors in patients with erectile dysfunction among patients with coronary artery disease— NHA Annual Scientific Meeting, 2001

13. Six months clinical outcomes in patients who underwent Adhoc PCI. A single Centre Experience — NHA Annual Scientific Meeting, 2001

14. A prospective review of caregiver adherence to pharmacotherapy in post first AMI patients in tertiary cardiac centre— NHA Annual Scientific Meeting, 2001

15. A review on warfarin therapy in INR Clinic in Penang Hospital— NHA Annual Scientific Meeting, 2002

16. The prevalence and influence of cardiovascular risk factors among coronary artery disease patients with erectile dysfunction —NHA Annual Scientific Meeting, 2002
17. S Stent Registry: A single center experience— NHA Annual Scientific Meeting, 2002
18. Immediate and long term outcome of Heparin Coated Stent— NHA Annual Scientific Meeting, 2002
19. A review on warfarin therapy in INR Clinic in Penang Hospital — 14th Asean Congress of Cardiology, 2002

B. Studies and trials (Co-investigator)

1. TROVAN CAP study --- Comparison of Trovofloxacin and Cefuroxime in treating community acquired pneumonia (International multi-center study) (1999)
2. Audit of management of asthma in medical wards, Penang Hospital (Group Leader) (1999)
3. Diovan Study—Comparison of Valsartan and Perindopril in patients with uncomplicated essential hypertension (2000)
4. HIRO 2 Study—An open prospectively randomised comparison of Hirulog versus Heparin in patients receiving aspirin and thrombolysis (Streptokinase) for the treatment of acute MI.(2001)
5. PACT Study --- Pravastatin in Acute Coronary Syndrome Trial.(2001)
6. ED Study --- Prevalence of erectile dysfunction in patients follow up in Cardiology Clinic, Penang Hospital.(2001)
7. A phase III study of the safety and antiviral activity of Entecavir (BMS-200475) vs Lamivudine in adults with Chronic Hepatitis B who are negative for Hepatitis B e Antigen.
8. ADVANCE study--- Action in Diabetes and Vascular Disease, Preterax and Diamicron MR Controlled Evaluation.
9. DIRECT study--- Comparison of direct stenting and conventional stenting in patients with type 2 diabetes mellitus.
10. A multinational, randomized, double-blind, placebo-controlled, forced-titration, 2X2 factorial design study of the efficacy and safety of long term administration of Nateglinide and Valsartan in the prevention of diabetes and cardiovascular outcomes in subjects with impaired glucose tolerance (IGT)
11. EXCELLENCE STUDY: 2019: An Observational Study on Prevalent Antihypertensive Prescription Practices in Private Hospitals in Malaysia. Protocol No: IC4- 06593-002- MYS